blue cross blue shield plans reverse course on glp-1 coverage BCBSM pulling back on GLP-1

IUPHAR review - glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target

GLP-1 drugs do the same

Keywords: Glucagon-like peptide 1 receptor agonists, inflammation, inflammatory bowel disease, neurodegenerative disorder, nuclear factor-kappa B, obesity, type-2 diabetes Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA), a category of medications frequently used to treat type 2 diabetes (T2D), comprise drugs such as exenatide, liraglutide, and semaglutide

Tirzepatide onset may also differ from semaglutide in immune-relevant contexts

Available at: 73 IsidroM

INTRODUCTION In patients with type 2 diabetes with overweight and no cardiovascular disease or moderate risk of cardiovascular disease, metformin is the recommended initial treatment (class IIa recommendation)